Transgene News and Research

RSS
Mary Ann Liebert peer-reviewed journal highlights advances in gene therapy for neurological diseases

Mary Ann Liebert peer-reviewed journal highlights advances in gene therapy for neurological diseases

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Life Technologies introduces CytoTune-iPS Reprogramming Kit

Life Technologies introduces CytoTune-iPS Reprogramming Kit

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Global gene therapy market to reach $300 million by 2015

Global gene therapy market to reach $300 million by 2015

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Intrexon to deploy Novici's GRAMMR technology in concert with UltraVector platform

Intrexon to deploy Novici's GRAMMR technology in concert with UltraVector platform

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Transposagen, CDI enter license agreement for iPS cell line production

Transposagen, CDI enter license agreement for iPS cell line production

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Simple protocol for determining Gross Chromosomal Rearrangement mutation rates

Simple protocol for determining Gross Chromosomal Rearrangement mutation rates

Maven Semantic announces updates to Bioinformatics medical professionals database

Maven Semantic announces updates to Bioinformatics medical professionals database

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Sigma Life Science announces global release of CompoZr Targeted Integration Kit

Sigma Life Science announces global release of CompoZr Targeted Integration Kit

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent